In 2022, a clinical study was conducted at the Dermalab Laboratory to evaluate the efficacy of an injectable hair filler containing polynucleotide compounds for the treatment of androgenetic alopecia (hereditary hair loss) in both men and women.
Individuals with mild to moderate hormonal hair loss, based on internationally recognized classification scales for male and female pattern hair loss, underwent treatment consisting of 10 injection sessions of the hair filler in the scalp area. All injections were performed by experienced dermatologists.
Assessments were carried out using digital photography, TrichoScan analysis, and the hair counting (combing) test.
The results demonstrated that treatment with this hair filler led to a significant reduction in hair shedding, along with an increase in hair shaft thickness and the number of terminal (thick) hairs. Additionally, 65% of patients experienced varying degrees of improvement in hair regrowth after completion of the treatment, and overall patient satisfaction with the treatment process was reported to be high.
